» Articles » PMID: 35106505

Four Groups of Type 2 Diabetes Contribute to the Etiological and Clinical Heterogeneity in Newly Diagnosed Individuals: An IMI DIRECT Study

Abstract

The presentation and underlying pathophysiology of type 2 diabetes (T2D) is complex and heterogeneous. Recent studies attempted to stratify T2D into distinct subgroups using data-driven approaches, but their clinical utility may be limited if categorical representations of complex phenotypes are suboptimal. We apply a soft-clustering (archetype) method to characterize newly diagnosed T2D based on 32 clinical variables. We assign quantitative clustering scores for individuals and investigate the associations with glycemic deterioration, genetic risk scores, circulating omics biomarkers, and phenotypic stability over 36 months. Four archetype profiles represent dysfunction patterns across combinations of T2D etiological processes and correlate with multiple circulating biomarkers. One archetype associated with obesity, insulin resistance, dyslipidemia, and impaired β cell glucose sensitivity corresponds with the fastest disease progression and highest demand for anti-diabetic treatment. We demonstrate that clinical heterogeneity in T2D can be mapped to heterogeneity in individual etiological processes, providing a potential route to personalized treatments.

Citing Articles

Characterizing Circulating microRNA Signatures of Type 2 Diabetes Subtypes.

Sulaiman F, Khyriem C, Dsouza S, Abdul F, Alkhnbashi O, Faraji H Int J Mol Sci. 2025; 26(2).

PMID: 39859351 PMC: 11766090. DOI: 10.3390/ijms26020637.


Identification of genetic loci enriched in obese or lean T2D cases in the Korean population.

Lim E, Cho Y Genes Genomics. 2024; 47(2):235-243.

PMID: 39693004 DOI: 10.1007/s13258-024-01602-x.


Clinical utility of novel diabetes subgroups in predicting vascular complications and mortality: up to 25 years of follow-up of the HUNT Study.

Bjarko V, Haug E, Langhammer A, Ruiz P, Carlsson S, Birkeland K BMJ Open Diabetes Res Care. 2024; 12(6).

PMID: 39577876 PMC: 11590787. DOI: 10.1136/bmjdrc-2024-004493.


Type 2 diabetes pathway-specific polygenic risk scores elucidate heterogeneity in clinical presentation, disease progression and diabetic complications in 18,217 Chinese individuals with type 2 diabetes.

Yu G, Tam C, Lim C, Shi M, Lau E, Ozaki R Diabetologia. 2024; 68(3):602-614.

PMID: 39531041 PMC: 11832604. DOI: 10.1007/s00125-024-06309-y.


Diabetes and obesity: leveraging heterogeneity for precision medicine.

Franks P, Sargent J Eur Heart J. 2024; 45(48):5146-5155.

PMID: 39523563 PMC: 11663485. DOI: 10.1093/eurheartj/ehae746.


References
1.
Florez J . Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes?. Diabetologia. 2008; 51(7):1100-10. DOI: 10.1007/s00125-008-1025-9. View

2.
Schwenk J, Gry M, Rimini R, Uhlen M, Nilsson P . Antibody suspension bead arrays within serum proteomics. J Proteome Res. 2008; 7(8):3168-79. DOI: 10.1021/pr700890b. View

3.
Koivula R, Forgie I, Kurbasic A, Vinuela A, Heggie A, Giordano G . Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia. 2019; 62(9):1601-1615. PMC: 6677872. DOI: 10.1007/s00125-019-4906-1. View

4.
Drobin K, Nilsson P, Schwenk J . Highly multiplexed antibody suspension bead arrays for plasma protein profiling. Methods Mol Biol. 2013; 1023:137-45. DOI: 10.1007/978-1-4614-7209-4_8. View

5.
Harrow J, Frankish A, Gonzalez J, Tapanari E, Diekhans M, Kokocinski F . GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 2012; 22(9):1760-74. PMC: 3431492. DOI: 10.1101/gr.135350.111. View